Anti-Human EGLN1 Polyclonal Antibody

Catalog No.

PHK54901

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human EGLN1 (Ala190-Phe426).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

C1orf12, SM-20, PHD2, Egl nine homolog 1, HPH-2, EGLN1, HIF-prolyl hydroxylase 2, HIF-PH2, Prolyl hydroxylase domain-containing protein 2, Hypoxia-inducible factor prolyl hydroxylase 2

Purification

Purified by antigen affinity column.

Accession

Q9GZT9

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Endothelial HIF2α suppresses retinal angiogenesis in neonatal mice by upregulating NOTCH signaling., PMID:38770916

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma., PMID:36439433

Endothelial Autocrine Signaling through CXCL12/CXCR4/FoxM1 Axis Contributes to Severe Pulmonary Arterial Hypertension., PMID:33804745

The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study., PMID:32090446

Intrabody against prolyl hydroxylase 2 ameliorates acetaminophen-induced acute liver injury in mice via concomitant promotion of angiogenesis and redox homeostasis., PMID:31855737

PHD2 exerts anti-cancer and anti-inflammatory effects in colon cancer xenografts mice via attenuating NF-κB activity., PMID:31838134

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor., PMID:29924941

Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis., PMID:26848160

Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells., PMID:23466866

Differential in vitro and cellular effects of iron chelators for hypoxia inducible factor hydroxylases., PMID:23097160

Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model., PMID:22772092

Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives., PMID:22460450

Src activates HIF-1α not through direct phosphorylation of HIF-1α specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway., PMID:21335603

Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis., PMID:21300765

Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis., PMID:20856199

Double immunohistochemical staining method for HIF-1alpha and its regulators PHD2 and PHD3 in formalin-fixed paraffin-embedded tissues., PMID:20216402

Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues., PMID:16324198

Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20., PMID:12379765

SM-20 is a novel 40-kd protein whose expression in the arterial wall is restricted to smooth muscle., PMID:8606489

[Anti-endometrial cancer monoclonal antibody "MSN-1" and its application to EmC-EIA method]., PMID:8361005

Document Download

Anti-Human EGLN1 Polyclonal Antibody.pdf